UPMC Enterprises
UPMC Enterprises is an investor named in the Raise Track Update as participating in Estuary Biotherapeutics' Series A.
- Type
- Venture capital firm
About
UPMC Enterprises participated in Estuary Biotherapeutics' $93 million Series A, announced on 2026-10-16. RA Capital Management led.
The Raise Track Update names UPMC Enterprises as an investor in: Estuary Biotherapeutics (2026-10-19).
This page is not indexed by search engines yet. It is promoted once it meets the quality gate for investor pages: a description from the firm's own website, a headquarters city and at least two two-sourced rounds on this site.
Funding rounds on RaiseTrack
| Company | Round | Date | Role |
|---|---|---|---|
| Estuary Biotherapeutics | Series A 2026 | 2026-10-16 | participant |
Sources
Last verified:
- https://estuarybio.com/news/estuary-series-a
Type: company announcement. Accessed 2026-10-19.
Estuary Biotherapeutics release, 16 October 2026. Names UPMC Enterprises as a participant in the Series A. - https://www.4biocapital.com/single-post/estuary-biotherapeutics-launches-with-103-million-to-advance-targeted-gene-therapies-for-kidney-dis
Type: official investor website. Accessed 2026-10-19.
4BIO Capital post, 16 October 2026. Names UPMC Enterprises as a participant. - https://www.fiercebiotech.com/biotech/estuary-emerges-stealth-103m-its-gene-therapies-kidney-disease
Type: reputable publication. Accessed 2026-10-19.
Fierce Biotech, labeled Oct 16, 2026, 6:30am. Names UPMC Enterprises as an investor in the Series A. - https://buttondown.com/raisetrack/archive/raise-track-update-2026-10-19/
Type: other verified public source. Accessed 2026-10-19.
Raise Track Update for 2026-10-19. Names this firm on Estuary Biotherapeutics' $93 million Series A.